A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.

ABSTRACT: Human IgG comprises four subclasses with different biological functions. The IgG3 subclass has a unique character, exhibiting high effector function and Fab arm flexibility. However, it is not used as a therapeutic drug owing to an enhanced susceptibility to proteolysis. Antibody aggregation control is also important for therapeutic antibody development. To date, there have been few reports of IgG3 aggregation during protein expression and the low pH conditions needed for purification and virus inactivation. This study explored the potential of IgG3 antibody for therapeutics using anti-CD20 IgG3 as a model to investigate aggregate formation. Initially, anti-CD20 IgG3 antibody showed substantial aggregate formation during expression and low pH treatment. To circumvent this phenomenon, we sy

SUBMITTER: Saito S 

PROVIDER: S-EPMC6459999 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature